CNN  — 

The pharmaceutical company Eli Lilly announced last week that a medication developed to treat diabetes, tirzepatide, also had a substantial effect on reducing weight.

Among the more than 900 adults with obesity and diabetes in a study, tirzepatide not only controlled their blood sugar but also helped those on the higher dose lose an average of 34 pounds, which was nearly 16% of their starting weight, according to a company news release. The participants took the drug for a year and five months.

Eli Lilly plans to file for approval by the US Food and Drug Administration to market tirzepatide for treating obesity.

Another pharmaceutical company, Novo Nordisk, manufactures the medication semaglutide, which the FDA has already approved to treat diabetes under the brand name Ozempic and to treat obesity under the brand name Wegovy. Celebrities have claimed to use it as a weight-loss tool, and its widespread use has triggered medication shortages.

How exactly do semaglutide and tirzepatide work? How promising are they to treat obesity? What are the side effects? Who is eligible? What if someone wants to lose a few pounds for a wedding or event — should they take them?

To help us with these questions, I spoke with CNN Medical Analyst Dr. Leana Wen. Wen is an emergency physician and professor of health policy and management at the George Washington University Milken Institute School of Public Health. She previously was Baltimore’s health commissioner.

CNN: Can you explain how medications like tirzepatide and semaglutide work?

Dr. Leana Wen: Both of these injection medications were initially developed to treat type 2 diabetes. In the process of doing clinical trials, research also found that they have a substantial effect on weight loss.